CJC-1295 + Ipamorelin vs Kisspeptin
CJC-1295 + Ipamorelin and Kisspeptin are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: CJC-1295 + Ipamorelin is combination — ghrh(1-29) analogue plus selective ghrelin-receptor agonist, while Kisspeptin is decapeptide (kisspeptin-10), kiss1 gene product fragment — different molecular classes with different handling consequences; their leading degradation routes differ (independent degradation of the two components at different rates, which is the defining stability characteristic of any blend. for CJC-1295 + Ipamorelin, tryptophan oxidation, accelerated by light for Kisspeptin), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
CJC-1295 + Ipamorelin — origin
This is a two-compound blend studied for complementary mechanisms rather than a single molecule. CJC-1295 is a modified GHRH(1-29) fragment with four amino-acid substitutions that resist enzymatic degradation. Ipamorelin is a pentapeptide ghrelin-receptor agonist notable for its selectivity — it was specifically developed to stimulate GH release without the cortisol and prolactin effects of earlier secretagogues like GHRP-6.
Kisspeptin — origin
Kisspeptin-10 is the C-terminal decapeptide of the KISS1 gene product, active at the KISS1 receptor (GPR54). It sits at the top of the reproductive signalling axis, studied for triggering GnRH release. The parent protein was first described as a metastasis suppressor, hence the older name metastin.
CJC-1295 + Ipamorelin research themes
GHRH-receptor and ghrelin-receptor agonism act through different mechanisms, which is the rationale for pairing them.
Developed specifically for GH release with minimal cortisol and prolactin effects — its defining pharmacological feature.
Studied for effects on the pattern of GH secretion rather than continuous elevation.
A common endpoint in the preclinical literature for GH-axis compounds.
Kisspeptin research themes
Studied as the upstream trigger of GnRH release and the downstream LH and FSH signalling cascade.
Examined as the endogenous ligand for the KISS1 receptor in reproductive neuroendocrine models.
The parent KISS1 product was first characterised in cancer-metastasis research, a separate strand of the literature.
CJC-1295 + Ipamorelin handling
- Confirm whether the labelled mass is total blend mass or per-component before calculating concentration.
- Reconstitute the full vial rather than attempting to subdivide dry material — the two components will not partition evenly in powder form.
- Protect from light and refrigerate.
Kisspeptin handling
- Reach room temperature before opening.
- Keep reconstituted solution out of direct light during long bench sessions.
- Aliquot and refrigerate.
Both third-party tested
Every Popular Peptides batch of CJC-1295 + Ipamorelin and Kisspeptin is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
CJC-1295 + Ipamorelin reference
Related comparisons
CJC-1295 + Ipamorelin and Kisspeptin are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.